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1999–2004, ages 16–64 years, were selected from a privately
insured claims database with 6+ million beneﬁciaries. Control
group was an age and gender matched cohort of randomly
chosen beneﬁciaries without epilepsy. All were required to have
continuous health coverage during 2004 (baseline) and 2005
(study period). Chi-squared tests were used to compare baseline
comorbidities. Wilcoxon rank-sum tests were used for univariate
comparisons of annual direct (medical and pharmaceutical) costs
to insurers during the study period. RESULTS: Patients with
epilepsy averaged 43 years old, and there were more females
(57%). Compared with controls, epilepsy patients had signiﬁ-
cantly higher rates of mental health disorders, comorbidities
included in the Charlson Comorbidity Index (e.g., cerebrovascu-
lar disease, congestive heart failure, COPD, rheumatologic
disease, cancer), migraine, and other neurological disorders. On
average, direct annual costs were signiﬁcantly higher for epilepsy
patients ($10,258) compared with controls ($3,862), difference
of $6,396, P < 0.0001. Outpatient services accounted for 34%,
inpatient services for 28%, and drug costs for 27% of epilepsy
patients’ annual direct costs. Among epilepsy patients, non-
epilepsy costs accounted for $8201 (80%) on average and
epilepsy-related costs (i.e., costs for antiepileptic drugs, claims
with an epilepsy or convulsions diagnosis, neurology visits, and
selected diagnostic procedures) accounted for $2057 (20%).
Approximately 13% ($1047) of non-epilepsy costs were attrib-
utable to mental health-related expenditures. CONCLUSIONS:
Patients with epilepsy had signiﬁcantly higher costs compared
with matched controls. The excess costs of epilepsy patients are
underestimated when looking only at epilepsy-related costs.
Epilepsy-related costs represented 20% of the annual direct costs
of epilepsy patients and almost one-third of the difference in costs
between epilepsy patients and controls.
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OBJECTIVES: A national multicentre retrospective study
(EPIZOD) based on medical records review was conducted
among a sample of general practitioners, dermatologists, neu-
rologists and anti-pain centers. Main EPIZOD objectives were
to estimate annual incidence of Herpes Zoster (HZ) and the
proportion of patients developing Post-Herpetic Neuralgia
(PHN) in France. PHN was deﬁned as “persistence of pain at
least one month after rash onset”. An economic study was
carried out in a sample of patients included in EPIZOD to
estimate costs associated with HZ and PHN management in
patients aged more than 50 in France. METHODS: Costs of
health resources utilization, including consultations, examina-
tions, treatments (i.e. drugs and non-pharmacological treat-
ments), hospitalizations and sick leaves, were valued according
to ofﬁcial tariffs and weighted by patients’ treatment patterns.
Estimations were calculated according to both Third Party
Payer (TPP) and societal perspectives. RESULTS: Among 862
HZ and 412 PHN patients included in EPIZOD, 108 and 88
patients, respectively, were recruited for the economic study.
Mean cost per HZ case was estimated to be €182.92 for TPP
and €346.78 for the society. Each PHN case was assessed to
cost on average €339.84 and €555.56 respectively. Main costs
drivers for TPP were treatments (about 50% of total costs),
followed by hospitalizations and medical consultations (about
20% each). Based on EPIZOD incidence estimations, annual
cost associated with HZ and PHN management would reach
€61.0 million for TPP and €108.5 million for the society. CON-
CLUSIONS: This study suggests that HZ and PHN are costly
diseases in France. In this context, our ﬁndings will be useful for
policymakers when assessing HZ and PHN control measures,
including the introduction of a vaccine.
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OBJECTIVES: Alzheimer’s disease is a chronic, progressive
disease, characterized by deterioration of cognitive function. The
prevalence rate of Alzheimer’s disease is 10 percent in people
over the age of 70, and 40 percent for people over age 90. There
is no cure for Alzheimer’s disease therefore the goal of treatment
is to control the signs and symptoms of the disease through
prescription medications. At the national level, research is
lacking in the area of prescription medication costs for Alzhe-
imer’s disease. The objectives of this study were to estimate the
number and cost of prescription medications for Alzheimer’s
disease in the United States. METHODS: The Medical Expendi-
tures Panel Survey is a nationally representative sample of the
non-institutionalized, civilian population in the United States.
Data from the 2004–2005 Medical Expenditures Panel Survey
were used to estimate the cost of prescription medications for
Alzheimer’s disease. To test for a difference between costs of
prescription medications for gender, a t-test was used. A series of
one-way ANOVA analyses were used with each of the remaining
demographic variables (age, marital status, income and region of
residence) serving as the independent variable and the cost of
Alzheimer’s prescription medications as the dependent variable.
RESULTS: Over 1.9 million people reported having Alzheimer’s
disease in 2004 and 2005. Over the two year period, these
patients reported having over 10 million prescriptions ﬁlled for
Alzheimer’s medications at a cost of over $1.3 billion in U.S.
dollars. CONCLUSIONS: The most rapidly growing segment of
the population by the year 2030 will be people over the age of 85.
Because life expectancy is increasing and the risk of developing
Alzheimer’s increases with age, this cost of prescription medica-
tions estimation has both current and future relevance for health
care insurers, providers, administrators, policy makers and
Alzheimer’s patients.
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OBJECTIVES: CF patients need specialized long-term medica-
tion. In order to support lung function inhalable pharmaceuticals
like bronchodilators, mucolytica or anti-inﬂammatory drugs are
used. Oral or inhalable antibiotic therapy is especially important
for patients whose lung has a chronic colonization with germs. In
case of pancreatic insufﬁciency digestive enzymes have to be
substituted and patients need an additional supplement of vita-
mins as well as high caloric food. All of these aspects lead to high
medication in CF patients. Hence, aim of this work is to analyse
medication mixtures and related costs for CF in Germany.
METHODS: Medication data was evaluated in seven different
outpatient CF centres. Data was recorded via medication lists by
the physicians reporting name of medication, dosage and phar-
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